PDUFA dates are the sharpest binary events in all of equities. A single FDA decision can double a stock or cut it in half before the close. Here's how experienced biotech traders approach these events — including the traps that kill most retail investors who try to play them blind.
In This Guide
Most stock-moving events — earnings, analyst upgrades, macro data — play out on a spectrum. PDUFA dates don't. The FDA delivers one of three verdicts: Approved, Complete Response Letter (CRL), or Extension. For small-cap biotechs where the drug under review is the entire pipeline, that decision determines whether the company survives.
This binary structure is why PDUFA stocks behave differently from the rest of the market:
In the weeks and days leading up to a PDUFA date, traders and institutions accumulate positions in anticipation of approval. This pre-approval run-up — often called the "PDUFA pop" or "PDUFA drift" — can be 20–100% above where the stock was 90 days out. When the approval comes, the initial gap is often smaller than the run-up that preceded it. When the CRL comes, the gap down hits a stock that was already trading on hope.
A PDUFA decision for Eli Lilly or Pfizer moves the stock 2–5% — it's one product in a massive portfolio. For a single-asset small-cap biotech, the same event can move 50–400% in either direction in a single session. The smaller the company and the more pipeline-dependent, the more violent the move.
Implied volatility (IV) on PDUFA stocks peaks just before the decision, then collapses immediately after — regardless of direction. Options buyers who correctly predict the direction still lose money if IV crush erases the premium they paid. This is one of the most expensive lessons in biotech options trading.
The bottom line: PDUFA dates create outsized return potential and outsized loss potential. They reward preparation and punish improvisation.
How you enter matters as much as what you enter. Here are the frameworks used by experienced biotech catalyst traders:
Binary events require binary-aware sizing. A common framework: size any PDUFA position as if you're willing to lose the entire position. For a high-PoA drug with a 90% historical approval rate, the expected loss scenario still happens 10% of the time — and when it does, it's often 60–80% of the stock's value. Running full position size into a binary event is a portfolio-management error even when the trade works.
Practical rule: PDUFA positions should represent at most 2–5% of portfolio value for most investors. For high-conviction plays where you've done deep due diligence, some traders go to 10% — but that's a ceiling, not a target.
Rather than buying the day before, experienced biotech traders start accumulating 30–90 days before the PDUFA date — before the run-up drives IV higher and price higher. This means:
Options can define risk precisely — the most valuable property in a binary event. Common approaches:
| Strategy | When to Use | IV Crush Risk |
|---|---|---|
| Long calls (OTM) | High-PoA drug, bought 4–8 weeks before date (lower IV) | HIGH if bought day-before |
| Defined-risk spreads (debit spread) | Limits max loss, reduces IV crush impact vs. naked long | MODERATE — short leg offsets |
| Straddle / strangle | Unknown direction — requires very large move to profit | VERY HIGH — both legs crushed |
| Protective puts on equity position | Hedging existing long position through binary event | MODERATE — functions as insurance |
The core principle: buy options well before the event when IV is lower, not the week of the PDUFA date when IV is at its peak. Many sophisticated biotech traders actually sell options (e.g., covered calls) into peak IV rather than buy.
The most important decision is made before the PDUFA date — not on it. Ask yourself:
Experienced biotech traders often sell half or two-thirds of a position before the PDUFA date, keeping a "free-roll" position funded by profits from the run-up. If it approves, they participate in upside. If it CRLs, they've already booked most of the gain.
Every PDUFA and AdCom entry on the dansfera.com catalyst calendar includes a Probability of Approval (PoA) score. Understanding what these scores mean — and what they don't mean — is critical for sizing trades correctly.
PoA scores on this calendar are Bayesian base rates from historical FDA approval data — not opinions, analyst estimates, or predictions about a specific drug. They answer the question: "For all drugs of this type that reached this stage, what percentage were approved?"
NDA/BLA applications with priority or orphan designations. High base rate means most drugs at this stage get approved — but the 7–15% failure rate still represents massive downside for investors.
Phase 3 trial readouts, CRL resubmissions, or drugs with manufacturing concerns flagged in the review. Nearly coin-flip probability — treat these as speculative bets, not base rate plays.
The base rate is your starting point. Adjust it mentally based on drug-specific signals:
Read the PDUFA Dates Explained guide for a full breakdown of how base rates are calculated and what each designation means.
The most common and most expensive mistake. Even a 90% PoA drug fails 10% of the time — and when it does, it often gaps down 60–80% at open with no opportunity to exit. Holding full position size through a binary event is not investing; it's gambling with a defined negative asymmetry on the loss side.
Advisory Committee meetings precede many PDUFA decisions and are often the most important data point available. A negative AdCom vote — even a split one — is a signal the FDA has serious concerns. Traders who ignore a negative AdCom and hold through the PDUFA date are betting the FDA will diverge from its own advisory panel. That happens, but it's the exception. The dansfera.com calendar tracks AdCom dates alongside PDUFA dates.
Implied volatility on PDUFA stocks peaks in the days before the decision. Buying calls or puts at peak IV means paying maximum premium for defined-life options that will collapse in value after the event — regardless of whether you're right about direction. This is IV crush, and it is brutal. Options should be accumulated weeks or months before the date, when IV is lower.
Buying a stock purely because it has an upcoming PDUFA date — without reading the clinical data, understanding the indication, or checking for CRL history — is the retail version of roulette. PoA scores are base rates, not verdicts. Doing actual due diligence (reading the FDA Briefing Documents when released, understanding the Phase 3 endpoints, checking for manufacturing concerns) is what differentiates profitable biotech traders from the majority who lose money in this space.
A positive AdCom vote raises the PoA significantly — but it is not a guarantee. The FDA occasionally diverges from advisory panel recommendations. More commonly, a positive AdCom leads to a "buy the rumor, sell the news" dynamic where the stock runs hard post-AdCom and then gives back gains on the actual approval as latecomers exit. Plan your entry and exit for the AdCom — not just the PDUFA date.
The dansfera.com catalyst calendar was built specifically for biotech catalyst investors. Here's how to use it to build a PDUFA trading watchlist:
Use the filter tabs at the top of the calendar to show only PDUFA dates or AdCom meetings. The urgency color-coding immediately surfaces what's imminent: 🔴 overdue, 🟠 today, 🟡 this week, 🔵 this month, 🟢 upcoming. Start with the "PDUFA" tab to see all active FDA action date entries.
Each calendar entry shows the PoA score and any FDA designation badges (Breakthrough Therapy, Priority Review, Fast Track, Orphan, Rare Pediatric). High PoA + priority review + orphan designation is the trifecta that typically commands the most investor attention — and the most pre-PDUFA run-up.
Each entry links to a dedicated drug detail page with:
This is where you check for CRL history before sizing up. A resubmission PoA penalty is applied automatically in the calendar for entries with documented CRL history.
Search the calendar for the same drug's ticker — if there's a matched AdCom entry a few months before the PDUFA date, that AdCom date is often where the more actionable trade happens. A positive AdCom sets up the pre-PDUFA drift. A negative AdCom is your signal to exit or not enter.
Build Your PDUFA Watchlist
85+ live catalyst entries. PoA scores on every PDUFA and AdCom. Free, no account needed.
Open the Catalyst Calendar →Here are upcoming PDUFA and high-priority catalysts currently tracked on the calendar. These are live entries — click through to the drug detail pages for full clinical context, PoA scores, and investor discussion.
The calendar is updated continuously as companies announce FDA filing acceptances and new PDUFA dates are set. View all upcoming catalysts →